Index 2002, AIDS Treatment News
Index 2002, AIDS Treatment NewsAaron Diamond Research Center 384
Abbreviated Guide ... HIV 380
Access to care 387
Achmat, Zackie 387
ACT UP 385
ACTG 384 trial changes 382
Activism 377
Activism 379
Activism 385
Activism 387
ADAP crisis 381
ADAP crisis 382
ADAP crisis 386
ADAP crisis 387
ADAP waiting list advice 381
ADAP 380
Advocacy 387
African Services Committee 385
AIDS Drug Assistance Program (see ADAP)
AIDSWatch lobbying 380
Amprenavir approved 378
Anti-HIV factor 384
Atazanavir 379
Avascular necrosis 379
Barcelona conference take-home messages 382
Barcelona conference visa problems 381
Barcelona conference Web sites 381
Barcelona online reports 382
Benefits issues 377
Bone problems 379
Buyers' club list 387
Chinese activist, Dr. Wan Yanhai 383
Coca Cola protest 384
Conferences and meetings list 378
Congress 387
Cost of international conferences 381
Counterfeit drugs 380
C-Reactive Protein 385
d4T -- side effects 378
d4T and lipoatrophy 378
Deca Durabolin availability problems 381
Defensins 384
Doctors Without Borders 385
Doha, Qatar 386
Drug interactions 377
Drug pricing 377
Efavirenz once daily 378
Epogen 380
Facial injections 378
Fundraising 377
FUZEON (see T-20)
Global Fund 379
Government AIDS Web site 386
Grossman, Dr. Howard, interview 383
Guidelines on metabolic complications 385
Health GAP 385
Heart disease prevention 377
Heart disease 385
Hepatitis C 384
HIV harm reduction 384
ICAAC conference, clinical trials 384
Integrase inhibitor 379
Intellectual property 385
Intellectual property 386
Interactions of drugs 377
Johns Hopkins short guide 380
Junk foods 377
Kaiser, Jon, M.D. 383
Lactic acidosis 378
Legal issues 377
Lipoatrophy -- drug changes 378
Lipodystrophy strategies 383
Marijuana lung report 385
Marijuana 379
Measles may suppress HIV 379
Medicaid crisis 387
Medicaid funding 380
Medical privacy rules 379
Medical research funding 377
Metabolic complications -- guidelines 385
MSF (Doctors Without Borders) 385
Nandrolone availability problems 381
Nandrolone generic 382
NATAF conference 382
NDRI (National Disease Research Interchange) 385
Network of People ... Nigeria 385
Neuromuscular weakness 378
Nevirapine patient assistance program 385
New drugs at Retroviruses conference 379
Nigeria -- patent meeting 385
Nonoxynol-9 dangers 381
Nonoxynol-9 dangers 384
Once-a-day dosing 383
Oxfam 385
Patents on pharmaceuticals 385
Patents on pharmaceuticals 386
Patient assistance programs 385
Peginterferon (hepatitis C) 384
PHATAM (Pan African HIV/AIDS Treatment Access Movement) 383
Philadelphia, AIDS Education Month 380
Political organizing 387
Prevention -- tenofovir 385
Pricing of drugs 377
Protease inhibitors 383
Remune controversy 380
Resistance testing 383
Retroviruses conference 378
Retroviruses conference 387
Retroviruses conference, Web coverage 378
Ribavirin (hepatitis C) 384
S-1360 integrase inhibitor 379
Search for a Cure 387
Serostim 380
Smallpox vaccination begins 386
Smallpox vaccination questions 387
Superinfection risk 383
T-20 383
T-20 384
Tenofovir access in poor countries 386
Tenofovir for prevention 385
Tenofovir 377
Tenofovir 383
Tipranavir 379
Tissue donation 385
TMC125 379
Topoisomerase inhibitors 379
Treatment Action Movement of Nigeria 385
Treatments, misc. experimental 377
U.S. government AIDS Web site 386
Vaccine Research Center, NIAID 385
Vaccine trial 385
Viread 377
Visa problems 381
Wan Yanhai released 384
Wan Yanhai 383
WTO trade rules 386
